Clinical trials: Immunogenicity, Vaccine
Vaccine Effectiveness, HPV Vaccination
A Trial to Establish Non-inferiority of Immunogenicity of a Single-dose of CERVAVAC® Quadrivalent HPV Vaccine Compared to the Gardasil® Quadrivalent Vaccine Among Girls and Boys Aged 9 to 14 Years and in Girls/Women Aged 15 to 20 Years in Zambia
The goal of this study is to compare the immune response of the single dose of the CERVAVAC vaccine with the single dose of Gardasil vaccine in girls/women aged 9 to 20 and boys aged 9 to 14 at 6 months, 12 months and 24 months…
- Conditions
- Vaccine Effectiveness, HPV Vaccination, Single Dose, Immunogenicity
- Trial name
- CervALONE (NCT07256912)
- Testing
- quadrivalent HPV vaccine
- Where
- Zambia
- Volunteers
- 1,266 people, healthy volunteers welcome
- Sponsor
- International Agency for Research on Cancer
Vaccination Adverse Event, Immunogenicity, Vaccine
Study Interchangeability Hep-B Vaccine Administered at Birth Dose
This trial is a randomized, double-blind, two arms parallel groups, prospective intervention study.
- Trial name
- NCT07854847
- Testing
- In-house Hepatitis B Vaccine, Registered Hepatitis B Vaccine
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Covid-19, Vaccine
Immunogenicity of COVID-19 Vaccine on Heterologous Schedule
This is a prospective, single blinded randomized homologous/heterologous prime-boost vaccine clinical study, designed to assess the immunogenicity of heterologous prime-boost immunization with AZD1222 and MVC-COV1901 in adults.
- Conditions
- Covid-19, Vaccine, Immunogenicity, Reactogenicity
- Trial name
- NCT05054621
- Testing
- Heterologous prime-boost schedule with AZD1222 and MVC-COV1901, Homologous prime-boost schedule with two doses of AZD1222
- Where
- Taiwan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
SARS-CoV2 Infection, Covid19
Pregnant and Lactating Individuals & Newborns COVID-19 Vaccination Prospective Cohort Study
The PLAN-V Study is an Ontario-based prospective, longitudinal study that will consist of extensive biosampling and detailed data collection from pregnant women/individuals, who have received the COVID-19 vaccine during their…
- Conditions
- SARS-CoV2 Infection, Covid19, Vaccine Reaction, Pregnancy Related
- Trial name
- PLAN-V (NCT05115617)
- Where
- 7 sites in Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Ottawa Hospital Research Institute
Newborn Vaccine Immunogenicity
Systems Biology to Identify Biomarkers of Neonatal Vaccine Immunogenicity
Infection is the most common cause of death in early life, especially for newborns and can be reduced by immunization but insufficient knowledge of how vaccines protect the very young limits their optimal use.
- Trial name
- EPIC-HIPC (NCT03246230)
- Testing
- Hepatitis B vaccine (HBV), Bacillus Calmette-Guérin (BCG)
- Where
- 2 sites in Papua New Guinea, The Gambia
- Volunteers
- 911 people, healthy volunteers welcome
- Sponsor
- Boston Children's Hospital
Safety of a Single Dose of COMVIGEN Vaccine, Reactogenicity of a Single Dose of COMVIGEN Vaccine
Immunogenicity and Safety of Comvigen (Bivalent) Vaccine
This study will assess the safety, reactogenicity and immunogenicity of a single dose of Comvigen (Bivalent, ChulaCov19 BNA159.2) vaccine or BIVALENT Pfizer/BNT vaccine as a booster among healthy males and non-pregnant females…
- Conditions
- Safety of a Single Dose of COMVIGEN Vaccine, Reactogenicity of a Single Dose of COMVIGEN Vaccine, Immunogenicity of a Single Dose of COMVIGEN Vaccine, Safety of a Single Dose of BIVALENT Pfizer/BNT Vaccine
- Trial name
- NCT05930730
- Testing
- Comvigen (Bivalent, ChulaCov19 BNA159.2), BIVALENT Pfizer/BNT vaccine
- Where
- 2 sites in Thailand
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Chulalongkorn University
Immunogenicity and Safety of a Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine Using for Sequential Immunization
Sequential Immunization With Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine in Health Adults Based on 3 Doses Inactivated COVID-19 Vaccine
COVID-19 is a novel coronavirus infection caused by respiratory droplets and contact transmission. With the spread of the epidemic, it has become a serious threat to global public health.
- Trial name
- NCT05373030
- Testing
- Recombinant adenovirus type-5-vectored COVID-19 vaccine
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Zhejiang Provincial Center for Disease Control and Prevention
Safety, Immunogenicity, Vaccine
Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23
The main objective of this study was to evaluate the immunogenicity and safety of the booster dose of COVID-19 inactivated vaccine and co-immunization with quadrivalent influenza vaccine and 23-valent pneumonia polysaccharide…
- Conditions
- Safety, Immunogenicity, Vaccine, COVID-19 Vaccines, Influenza Vaccines
- Trial name
- QIV;PPV23 (NCT05298800)
- Testing
- Vaccine
- Where
- 3 sites in China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
Microbiome, Vaccine
Gut Microbiota, the Potential Key to Modulating Humoral Immunogenicity of New Platform COVID-19 Vaccines
Vaccination is the best way to mitigate the coronavirus disease 2019 (COVID-19) pandemic, but the vaccine immunogenicity may be quite variable from person to person.
- Conditions
- Microbiome, Vaccine, Covid-19, SARS-CoV-2
- Trial name
- NCT05150834
- Testing
- This is observational study
- Where
- South Korea
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Korea University Guro Hospital
Covid19, Vaccine
Immunogenicity of the ChAdox1 n CoV-19 Vaccine With 12-dose Vial
ChAd0x1 nCoV-19 (AZD 1222) is the main vaccine that is planned to roll-out in Thailand and involve vaccinating people especially in high-risk categories.
- Conditions
- Covid19, Vaccine, Immunogenicity
- Trial name
- NCT04961385
- Testing
- Immunogenicity after first dose of participants who received first dose of ChAdox-1 n COV-19 vaccine
- Where
- Thailand
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bangkok Metropolitan Administration Medical College and Vajira Hospital
Gardasil Vaccine, Stem Cell Transplant
Gardasil Vaccination in Post Stem Cell Transplant Patients
Background: Gardasil , a recently approved vaccine for the sexually transmitted human papillomavirus (HPV), provides immunity to four types of HPV that are associated with genital warts and cervical, vaginal, and vulvar precancer…
- Conditions
- Gardasil Vaccine, Stem Cell Transplant, Immunogenicity
- Trial name
- NCT01092195
- Testing
- Gardasil
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Adverse Effect and Immunogenicity of Vaccine
Immunogenicity and Safety of A Lyophilized Purified Human Diploid Cell Rabies Vaccine .
Rabies is caused by rabies virus with a 100% mortality rate in humans. Most of cases occur in Africa and Asia, mainly in underserved populations. Rabies is a vaccine-preventable disease in both humans and animals.
- Trial name
- NCT03971370
- Testing
- Human diploid cell rabies vaccine (Minhai Biothechnology Co., Ltd), Human diploid cell rabies vaccine (Chengdu Kanghua Biological Products Co., Ltd.)
- Where
- China
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
HPV Vaccines Immunogenicity and Safety
Immunogenicity and Safety of Gardasil-9 and Cervarix
A ninevalent HPV vaccine (Gardasil-9) has been recently approved for clinical use. No data on immunogenicity and safety of interchangeable use of the ninevalent and the bivalent vaccine (Cervarix) are available.
- Trial name
- NCT02567955
- Testing
- Immunogenicity two doses of Gardasil-9, Immunogenicity Cervarix and Gardasil-9
- Where
- Canada
- Volunteers
- 376 people, healthy volunteers welcome
- Sponsor
- Laval University
Immunogenicity, Vaccine, Immunologic Memory
Immunological Memory Against Pneumococcus Induced by 3 Infant PCV 13 Vaccination Schedules
The purpose of this study is to evaluate the establishment of immunological memory between the 3 different infant vaccination schedules with the 13-valent pneumococcal conjugate vaccine (PCV13) currently in use.
- Trial name
- NCT03405805
- Testing
- 13-valent pneumococcal conjugate vaccine (PCV13)
- Where
- Greece
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Aghia Sophia Children's Hospital of Athens
Vaccines, HIV
A Phase II Trial to Assess the Safety and Immunogenicity of DNA Priming Administered by the ID Zetajet® With or Without ID Derma Vax™ Electroporation Followed by IM MVA Boosting in Healthy Volunteers in Tanzania and Mozambique
Electroporation will increase the efficiency of DNA priming in terms of immune responses and will lead to a dose sparing DNA vaccine regimen.
- Conditions
- Vaccines, HIV, Safety, Immunogenicity
- Trial name
- TaMoVac II (NCT01697007)
- Testing
- HIVIS DNA vaccine, Zetajet, Derma Vax Electroporation
- Where
- 3 sites in Mozambique, Tanzania
- Volunteers
- 198 people, healthy volunteers welcome
- Sponsor
- Muhimbili University of Health and Allied Sciences
Immunocompromised Patients, Safety of Pandemic Influenza A (H1N1)Vaccine
Evaluation of Pandemic Influenza A (H1N1) Vaccine in Chronic and or Immunocompromised Patients, Elderly and Pregnants
The objective of this study is to describe the safety and immunogenicity of a non-adjuvanted vaccine against pandemic influenza A (H1N1)in patients with chronic and or immunocompromised disease, elderly and pregnants.
- Conditions
- Immunocompromised Patients, Safety of Pandemic Influenza A (H1N1)Vaccine, Immunogenicity of Pandemic Influenza A (H1N1)Vaccine
- Trial name
- NCT01218685
- Testing
- Split inactivated A/California/7/2009 (H1N1) (NYMC X-179A) VIRUS
- Where
- Brazil
- Volunteers
- 1,152 people, healthy volunteers welcome
- Sponsor
- Butantan Institute